

OPTIMA HEALTH PLAN

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-800-750-9692. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. Incomplete form will delay authorization process.

Drug Requested (select one below):

SGLT2 Drugs

MEDICAID ONLY

<input type="checkbox"/> Invokana® (canagliflozin)	<input type="checkbox"/> Farxiga® (dapagliflozin)	<input type="checkbox"/> Jardiance® (empagliflozin)
<input type="checkbox"/> Invokamet®/Invokamet® XR (canagliflozin/metformin/metformin ER)	<input type="checkbox"/> Xigduo® XR (dapagliflozin/metformin ER)	<input type="checkbox"/> Glyxambi® (empagliflozin/linagliptin)
<input type="checkbox"/> Synjardy®/Synjardy® XR (empagliflozin/ metformin)		

DRUG INFORMATION: Complete information below. Authorization process will be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy:** _____

Diagnosis: _____ **ICD Code, if applicable:** _____

- **DO NOT INITIATE or CONTINUE therapy for:**
 - Invokana® or Invokamet/XR® if eGFR is **below** 45ml/min/1.73m²
 - Farxiga™ or Xigduo™ if eGFR is **below** 60ml/min/1.73m²
 - Jardiance®, Glyxambi® or Synjardy/XR® if eGFR is **below** 45ml/min/1.73m²
- These medications are **NOT** indicated for weight loss or the treatment of hypertension.

CLINICAL CRITERIA: Check below **ALL** that apply. Boxes **must** be checked to qualify or authorization process will be delayed.

- Patient has tried and failed at least **30 days of therapy** with **metformin**
AND
- Patient has tried and failed at least **30 days of therapy** with **TWO (2)** of the following: ***NOTE: A DPP-IV inhibitor MUST be tried for Glyxambi approval***
 - sulfonylurea
 - Dipeptidyl Peptidase (DPP)-IV inhibitor
 - Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist
- Patient's estimated Glomerular Filtration Rate (eGFR) _____ Date collected: _____
(NOTE: eGFR must be current, collected within the past 12 months)

****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.****

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.

Patient Name: _____

Member Optima #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

DEA OR NPI #: _____

* Approved by the Pharmacy and Therapeutics Committee: 11/17/2016
REVISED/UPDATED: 3/28/2017; 5/4/2017; 5/17/2017; 8/17/2017